VisualSonics Photoacoustics AACR Release

  • 458 views
Uploaded on

The new system has been designed for use in pre-clinical research and could herald major breakthroughs in cancer research; however, human applications of the technology are envisioned in the near …

The new system has been designed for use in pre-clinical research and could herald major breakthroughs in cancer research; however, human applications of the technology are envisioned in the near future.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
458
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
1
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Contact: VisualSonics: Shailja Tewari (416) 484-5220 SonoSite: Lisa Fritzky (425) 951-1375 VISUALSONICS ANNOUNCES NEXT GENERATION IN VIVO IMAGING TECHNOLOGY TO MAKE STRIDES IN CANCER RISK REDUCTION, EARLY DETECTION, PATIENT CARE, AND SURVIVORSHIP Major imaging breakthrough: The launch of VisualSonics Vevo LAZR photoacoustic imaging system enables pre-clinical researchers to visualize structural, molecular and functional attributes of tumors simultaneously “With Photoacoustics, we can see at the molecular level what effect a drug is having on cancer cells - it provides unparalleled insights into how cancer sustains itself and it’s only a matter time before we begin seeing practical application in humans” -Stanislav Emelianov, Associate Professor and Associate Chair for Research, Department of Biomedical Engineering, University of Texas at AustinTORONTO, Canada – April 4, 2011 – VisualSonics Inc., a leader in real time, in vivo,high-resolution micro-imaging systems and a wholly-owned subsidiary of SonoSite Inc.,(Nasdaq:Sono), is demonstrating the recently announced Vevo® LAZR PhotoacousticsImaging system at the American Association of Cancer Research’s annual conference (April2-6, 2011, Orlando, FL)The new system has been designed for use in pre-clinical research and could herald majorbreakthroughs in cancer research; however, human applications of the technology areenvisioned in the near future.“The Vevo LAZR is a crucial breakthrough, with wide ranging implications for cancerresearch. In recent years, the fight against cancer has centered on stopping growth usingdrugs (anti-angiogenesis therapeutics, for instance). If angiogenesis can be stopped or
  • 2. prevented from occurring, tumor growth can be controlled and significantly reduce harm totheir hosts,” added Dr. Emelianov.Furthermore, the ability to see the effect that a drug is having on the tumor growth is aninvaluable asset in the development of cancer therapeutics. In practical terms, this meansresearchers will be able to observe tumor biology in a living host organism (mice and rats)without having to biopsy the actual tumor itself. Currently, researchers are often required torely on ex vivo techniques such as histology and immunohistochemistry to obtain molecularinformation inside a tumor. The in vivo approach reduces the amount of animals required forresearch studies by allowing the same animal to be followed throughout the diseasedevelopment and treatment.Dr. Emelianov continued, “Being able to look at molecular level cell physiology, and to do soin a living organism, will greatly facilitate our understanding of how cancer spreads from themicro to the macro level, giving unparalleled insights into how tumors grow and metastasizewithin human tissue.”“The Vevo LAZR photoacoustics system is a breakthrough in-vivo imaging technology,”said Anil Amlani, VisualSonics’ President and CEO. “Advancements featured in this productwill enable oncology researchers to accelerate their research into understanding of the innerworkings of the cancerous cell and the host tissue in which it resides. The ability to conductthis microscopic level research in a living organism, non-invasively and in real-time will helpour customers to turn groundbreaking science into lifesaving care, at an even greater speed.”“The launch of the Vevo LAZR technology further demonstrates our commitment inproviding game changing imaging technology to advance pre-clinical research,” Kevin M.Goodwin, SonoSite’s President and CEO. “We are confident that the photoacousticstechnology will provide never-before-seen insights into cancer research and will have astrong impact on the discovery of new therapeutics.”The Vevo LAZR system supports VisualSonics continuous efforts to provide researcherswith innovative solutions to improving pre-clinical research. Applications for the VevoLAZR system range from lymph node imaging, study of hemoglobin and oxygen saturation,and targeted imaging of tumor biomarkers. In addition to cancer biology, this cutting-edge
  • 3. imaging system will benefit other areas of research such as diabetes, neurosciences, as well asdevelopmental and reproductive biology.Researchers are invited to experience a demonstration of the Vevo LAZR system by visitingVisualSonics at booth #2171 at AACR.About VisualSonicsVisualSonics is the world leader in real time, in vivo, high-resolution micro imaging systemsdesigned specifically for preclinical research and a wholly-owned subsidiary of SonoSite,Inc. (Nasdaq:Sono). The Company’s cutting edge technologies allow researchers at theworld’s most prestigious pharmaceutical and biotechnology companies, hospitals anduniversities to conduct research in cardiovascular, cancer, neurobiology and developmentalbiology areas. The micro imaging technologies support research applications that includegenetic research, phenotypic studies and drug development. VisualSonics micro imagingplatforms combine high-resolution, real time in vivo imaging at reasonable cost with ease-of-use and quantifiable results.About SonoSiteSonoSite, Inc. (www.sonosite.com) is the innovator and world leader in bedside and point-of-care ultrasound and an industry leader in ultra high-frequency micro-ultrasound technologyand impedance cardiography equipment. Headquartered near Seattle, the company isrepresented by fourteen subsidiaries and a global distribution network in over 100 countries.SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinicalspectrum by cost-effectively bringing high-performance ultrasound to the point of patientcare.Forward-looking Information and the Private Litigation Re form Act of 1995Certain statements in this press release relating to the expected benefits of the Vevo LAZR Photoacoustics Imagingtechnology, including market acceptance of products incorporating Vevo LAZR Photoacoustics Imaging technology andnew market and sales opportunities for SonoSite, and other statements regarding future results are “ forward-lookingstatements” for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. T heseforward-looking statements are based on the opinions and estimates of our management at the time the statements are madeand are subject to risks and uncertainties that could cause actual results to differ materially from those expected or impliedby the forward-looking statements. T hese statements are not guaranties of future performance and are subject to known andunknown risks and uncertainties and are based on potentially inaccurate assumptions. Factors that could cause actual resultsto differ from the forward-looking statements include: the risk that the technology will not yield the expected potentialbenefits, including the risk that we are unsucce ssful in achieving market acceptance of this technology, and the potentialfor competitive technologies, as well as other factors contained in the Item 1A. “ Risk Factors” section of SonoSite, Inc.’smost recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. We caution readers not toplace undue reliance upon these forward-looking statements that speak only as to the date of this release. We undertake noobligation to publicly revise any forward-looking statements to reflect new information, events or circumstances after thedate of this release or to reflect the occurrence of unanticipated even.